DNA damage checkpoint kinases in cancer
DNA damage response (DDR) pathway prevents high level endogenous and environmental DNA damage being replicated and passed on to the next generation of cells via an orchestrated and integrated network of cell cycle checkpoint signalling and DNA repair pathways. Depending on the type of damage, and where in the cell cycle it occurs different pathways are involved, with the ATM-CHK2-p53 pathway controlling the G1 checkpoint or ATR-CHK1-Wee1 pathway controlling the S and G2/M checkpoints. Loss of G1 checkpoint control is common in cancer through TP53, ATM mutations, Rb loss or cyclin E overexpression, providing a stronger rationale for targeting the S/G2 checkpoints. This review will focus on the ATM-CHK2-p53-p21 pathway and the ATR-CHK1-WEE1 pathway and ongoing efforts to target these pathways for patient benefit.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Expert reviews in molecular medicine - 22(2020) vom: 08. Juni, Seite e2 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Smith, Hannah L [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.06.2021 Date Revised 08.06.2021 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1017/erm.2020.3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310877881 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310877881 | ||
| 003 | DE-627 | ||
| 005 | 20231225141040.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1017/erm.2020.3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1036.xml |
| 035 | |a (DE-627)NLM310877881 | ||
| 035 | |a (NLM)32508294 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Smith, Hannah L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a DNA damage checkpoint kinases in cancer |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.06.2021 | ||
| 500 | |a Date Revised 08.06.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a DNA damage response (DDR) pathway prevents high level endogenous and environmental DNA damage being replicated and passed on to the next generation of cells via an orchestrated and integrated network of cell cycle checkpoint signalling and DNA repair pathways. Depending on the type of damage, and where in the cell cycle it occurs different pathways are involved, with the ATM-CHK2-p53 pathway controlling the G1 checkpoint or ATR-CHK1-Wee1 pathway controlling the S and G2/M checkpoints. Loss of G1 checkpoint control is common in cancer through TP53, ATM mutations, Rb loss or cyclin E overexpression, providing a stronger rationale for targeting the S/G2 checkpoints. This review will focus on the ATM-CHK2-p53-p21 pathway and the ATR-CHK1-WEE1 pathway and ongoing efforts to target these pathways for patient benefit | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a ATM | |
| 650 | 4 | |a ATR | |
| 650 | 4 | |a CDK1 | |
| 650 | 4 | |a CDK2 | |
| 650 | 4 | |a CHK1 | |
| 650 | 4 | |a CHK2 | |
| 650 | 4 | |a DNA damage response | |
| 650 | 4 | |a WEE1 | |
| 650 | 4 | |a cell cycle | |
| 650 | 4 | |a p53 | |
| 650 | 7 | |a Cell Cycle Proteins |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Protein Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.- |2 NLM | |
| 650 | 7 | |a Checkpoint Kinase 2 |2 NLM | |
| 650 | 7 | |a EC 2.7.1.11 |2 NLM | |
| 650 | 7 | |a Protein-Tyrosine Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a WEE1 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.2 |2 NLM | |
| 650 | 7 | |a ATR protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a Ataxia Telangiectasia Mutated Proteins |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a Checkpoint Kinase 1 |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 700 | 1 | |a Southgate, Harriet |e verfasserin |4 aut | |
| 700 | 1 | |a Tweddle, Deborah A |e verfasserin |4 aut | |
| 700 | 1 | |a Curtin, Nicola J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert reviews in molecular medicine |d 1997 |g 22(2020) vom: 08. Juni, Seite e2 |w (DE-627)NLM143073478 |x 1462-3994 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2020 |g day:08 |g month:06 |g pages:e2 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1017/erm.2020.3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2020 |b 08 |c 06 |h e2 | ||